| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530363000 |
Serum albumin, e.g., BSA, HSA, etc.
| 50 |
| 530367000 |
Ovalalbumin, e.g., avidin, conalbumins, etc.
| 13 |
| 530369000 |
Separation, purification or synthesis
| 10 |
| 530365000 |
Lactalbumin, e.g., milk source, etc. | 2 |
| 20120238727 | DECORIN COMPOSITIONS AND USE THEREOF - The present invention relates to improved decorin compositions and methods of their production. | 09-20-2012 |
| 20130197195 | Covalent Immobilization of Molecules Comprising an Amino Group - There is provided a method for covalent immobilization of at least one molecule comprising at least one amino group, said method comprising the sequential steps of: a) providing a surface comprising —SH groups, b) oxidizing the surface comprising —SH groups using redox reactions in the presence of noble metal ions, and c) contacting the surface with at least one molecule comprising at least one amino group to obtain a covalent binding of the at least one molecule to the surface, wherein said at least one amino group is involved in obtaining said covalent bond. The immobilized molecules are immobilized via stable covalent bonds. The method is more versatile since it can be performed as a one step method. All reaction steps are performed in aqueous solution. All steps can be performed at room temperature. The chemicals used are less expensive and less toxic compared to the prior art. | 08-01-2013 |
| Entries |
| Document | Title | Date |
|---|
| 20080306245 | Method For The Production Of Albumen Conjugates With Non-Steroidal Antirheumatic Drugs (Nsar) - The present invention concerns NSAR (non-steroidal antirheumatic agents)-protein conjugates and in particular NSAR-albumin conjugates, processes for their production and their use as pharmaceutical preparations especially for treating inflammations. | 12-11-2008 |
| 20080312415 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION - This invention relates to enfuvirtide peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to enfuvirtide derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections. | 12-18-2008 |
| 20090182125 | Porphyrin compound, albumin inclusion compound thereof and artificial oxygen carrier - A porphyrin compound represented by general formula (A): | 07-16-2009 |
| 20100022753 | METHOD FOR MODIFYING THIOL GROUP - A method for modifying a thiol group is provided. The method includes: providing a first material containing at least one sulfhydryl group; providing a second material containing at least one thiourea group; and reacting the first material with the second material in the presence of copper (II) ions to quickly form a disulfide bond between the sulfhydryl group and the thiourea group, wherein the disulfide bond can be easily reduced. | 01-28-2010 |
| 20100087627 | FGFR Extracellular Domain Acidic Region Muteins - Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided. | 04-08-2010 |
| 20100184955 | ANTICANCER PRODRUG SENSITIVE TO TARGET PROTEASE - Provided is an anticancer prodrug sensitive to a target protease. The anticancer prodrug includes an anticancer drug, peptide that is specifically decomposed by the target protease excessively secreted by cancer cells, and a polymer that is specifically accumulated at a target cancer site. When the inactive anticancer prodrug is administered, the anticancer prodrug is accumulated at the target caner site and then the peptide is decomposed by irradiation of radioactive rays, thereby releasing an active anticancer drug at the target caner site. Accordingly, destruction of normal cells can be minimized and a high anticancer therapeutic effect can be obtained by using a small amount of the anticancer drug administered and a small amount of radioactive rays irradiated. | 07-22-2010 |
| 20100222554 | Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides - The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. I.e., the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide. | 09-02-2010 |
| 20100331525 | ANTITUMORAL AGENTS WITH A BENZOPHENANTHRIDINE STRUCTURE AND FORMULATIONS CONTAINING THEM - The use of benzophenanthridine alkaloids and the salts thereof for the preparation of medicaments for the treatment of tumors is disclosed. | 12-30-2010 |
| 20110230644 | MICROBUBBLES FOR AFFINITY SEPARATION - The present invention relates to methods, compositions and kits for affinity isolation, affinity purification and affinity assay based on microbubbles coated with an affinity molecule. Particularly, the invention provides protein microbubbles coated with an affinity molecule. In addition, the invention provides glass microbubbles coated with an affinity molecule. Methods of using the microbubbles of the invention for isolating analytes and cells are specifically provided. | 09-22-2011 |
| 20120046447 | METHOD FOR PRODUCING CONJUGATE OF THYROXINE AND ALBUMIN - It is an object of the present invention to provide a method for producing a conjugate of thyroxine and albumin with higher purity. The present invention provides a method for producing a conjugate of thyroxine and albumin which comprises: step (a) of converting a carboxyl group in thyroxine having a carboxyl group to be linked to albumin into an active ester and allowing the thyroxine to react with albumin, so as to prepare a conjugate of thyroxine and albumin; and step (b) of purifying the conjugate with the use of an acidic mixed aqueous solvent in which the thyroxine having a carboxyl group to be linked to albumin is dissolved but albumin is not precipitated. | 02-23-2012 |
| 20120130049 | ALBUMIN-AMYLOID PEPTIDE CONJUGATES AND USES THEREOF - The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease. | 05-24-2012 |
| 20130041134 | METHODS FOR PREPARING POLYETHYLENE GLYCOL MALEIMIDE USING N-(2-HYDROXYETHYL) MALEIMIDE AS A STARTING MATERIAL - The present invention relates generally to methods for preparing polyethylene glycol maleimide (“PEG-Mal”). More specifically, the present invention relates to methods for synthesizing desired molecular weight PEG-Mal by direct ethoxylation of N-(2-hydroxyethyl)maleimide under specific reaction conditions. | 02-14-2013 |
| 20130165637 | USE OF G-CSF DIMER IN THE TREATMENT OF NEUTROPENIA - This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe neutropenia for the post-chemotherapy cancer patients. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased, providing a better effect in the treatment of neutropenia. | 06-27-2013 |
| 20140213765 | Albumin tissue scaffold - A tissue scaffold that made of albumin having continuous solid network and void are disclosed. Methods for preparing albumin tissue scaffolds from animal albumins are also disclosed. | 07-31-2014 |
| 20140235825 | BIOCOMPATIBLE PHASE INVERTIBLE PROTEINACEOUS COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME - Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications. | 08-21-2014 |
| 20140343253 | PLASMA PROTEIN FRACTIONATION BY SEQUENTIAL POLYACID PRECIPITATION - There is a recognized need for novel, more simplified, approaches to isolation of plasma from whole blood, as well as a need to isolate cell-free plasma fractions containing different plasma proteins. Methods are divulged for use of aqueous phase systems, formed in blood or blood containing solutions via addition of a single polymer at relatively low concentration, to effect isolation (clarification) of plasma proteins from blood cells. Methods are also divulged to replace widely used Cohn-type plasma protein fractionation which is based on sequential addition of up to 40% (v/v) ethanol and other precipitants, with simple sequential addition of a polyacid. The latter results in isolation of plasma protein fractions (i.e. fibrinogen, immunoglobulin, albumin) in sequence similar to that obtained with Cohn Fractionation and therefore may be suitable for use to reduce solvent use and solvent-related process complications in existing plasma protein purification processes. It may also support use of polymeric film based containers in novel solvent free plasma fractionation processes. The methods disclosed may also be suitable for use in smaller scale plasma protein isolation, in research and diagnostic applications. The general methodologies are robust and can function over a broad range of process variables such as temperature and pH. | 11-20-2014 |
| 20160184453 | Carrier-Antibody Compositions and Methods of Making and Using the Same - Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. | 06-30-2016 |
